Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda selects target from Lexicon alliance
The therapeutic target, LG474, was discovered by Lexicon in its Genome5000 program. In July 2004, Lexicon and Takeda entered into an alliance to develop new drugs directed against
The therapeutic target, LG474, was discovered by Lexicon in its Genome5000 program. In July 2004, Lexicon and Takeda entered into an alliance to develop new drugs directed against
The protocol of the trial has been modified to increase the number of stem cells that engraft in a patient’s bone marrow. In the upcoming trial, which is
The researchers’ hypothesis, published by The Lancet, suggests that, although chemotherapy for avian influenza is a substantial jump in thinking, the notion of using such therapy could still
The blast is said to have occurred at the company’s Irvine, North Ayrshire manufacturing site, which produces antibiotics and active pharmaceuticals in bulk. The 100-acre facility is GlaxoSmithKline’s
Signet plans to offer assays to investigators conducting research into the detection and management of acute and chronic diseases. Acute inflammation can result from sepsis, meningitis, respiratory infection,
DelSite is developing a nasal powder vaccine for pandemic avian influenza that combines its proprietary GelVac vaccine delivery system with an avian H5 influenza whole virion antigen. Preclinical
D93 is an investigatory, humanized, monoclonal antibody with a novel anti-angiogenic and tumor inhibitory mechanism of action. Preclinical studies with the compound have demonstrated its ability to reduce
The completed acquisition provides Albany Molecular Research (AMRI) with an immediate presence in Europe. In combination with AMRI’s facilities in the US and Asia, the acquisition enhances the
Pennsaid is a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries. The trial involved
“Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. The acquisition